natgillin/translations-raw huggingface dataset:
&gt; 9 years.
 9 godina.
&gt; 90 to ≤ 110
&gt; 90 do ≤ 110
&gt; age appropriate ULN**
&gt; GGN-a prikladnog za godine
&gt; ULN
&gt; GGN
&gt; 1 log reduction in HIV RNA or
&gt; 1 log smanjenje HIV RNA ili
&gt; 1 to ≤ 2 years
&gt; 1 do ≤2 godine
&gt; 1 to ≤2 years
&gt; 1 do ≤2 godine
&gt; 1,500 cells/mm3, then reduce cabazitaxel dose from 25 mg/m2 to 20 mg/m2.
&gt; 1500 stanica/mm3, a zatim smanjiti dozu kabazitaksela s 25 mg/m2 na 20 mg/m2.
&gt; 10 to ≤20 x ULN
&gt; 10 do ≤ 20 x GGN
&gt; 10 ULN
&gt; 10 GGN
&gt; 10 × ULN (grade 4)
&gt; 10 × GGN (4. stupanj)
&gt; 10% to ≤15%
&gt; 10% do ≤ 15
&gt; 10,000 – 100,000 copies/ml
&gt; 10 000 – 100 000 kopija/ml
&gt; 10,000 – 100,000 copies/ml
&gt; 10000 – 100 000 kopija/ml
&gt; 10.0 × ULN (Grade 4)
&gt; 10,0 × GGN (stupanj 4)
&gt; 100,000
Virološki neuspjeh
&gt; 100,000 copies/ml
&gt; 100 000 kopija/ml
&gt; 100,000 copies/ml, n (%)
&gt; 100 000 kopija/ml, n (%)
&gt; 100,000 copies/ml, n (%)
&gt; 100,000 kopija/ml, n (%)
&gt; 1000/ul
&gt; 1000/ul
&gt; 12 to ≤18 years
&gt; 12 do ≤ 18 godina
&gt; 12 to ≤18 years
&gt; 12 do ≤18 godina
&gt; 14 ml/kg/month of PRBC (approx.
&gt; 14 ml/kg/mjesec KE-a (otprilike
&gt; 15% to ≤20%
&gt; 15% do ≤ 20
&gt; 18 to ≤64 years
&gt; 18 do ≤ 64 godina
&gt; 1X – 3X upper normal limit
&gt; jednostruka – trostruka gornja normalna granica
&gt; 2 for 7 patients.
&gt; 2 za 7 bolesnika.
&gt; 2 months N=5 (%)
&gt; 2 mjeseca N = 5 (%)
&gt; 2 to ≤5 years
&gt; 2 do ≤5 godina
&gt; 2.0x ULN
2,0 x GGN
&gt; 20 ULN
&gt; 20 GGN
&gt; 20 x ULN
&gt; 20 x GGN
&gt; 20 × ULN (Grade 4)
&gt; 20 × GGN (4. stupanj)
&gt; 20% none
&gt; 20% nijedna
&gt; 20% to ≤25%
&gt; 20% do ≤ 25
&gt; 200,000/mm3.
&gt; 200 000/mm3.
&gt; 21 mg/kg/day
&gt; 21 mg/kg/dan
&gt; 2xULN (N=139)
&gt; 2xGGN (N=139)
&gt; 3 and ≤ 5 x ULN: Confirm levels and if confirmed, reduce the daily dose or stop treatment and monitor liver function at least every 2 weeks.
&gt; 3 i  5 x GGN: Potvrditi vrijednosti i ukoliko je potvrđeno, smanjiti dnevnu dozu ili obustaviti liječenje i pratiti funkciju jetre barem svaka 2 tjedna.
&gt; 3 and  5 x ULN: Confirm levels and if confirmed, reduce the daily dose or stop treatment and monitor liver function at least every 2 weeks.
&gt; 3 i  5 x GGN: Potvrditi vrijednosti i ukoliko je potvrđeno, smanjiti dnevnu dozu ili obustaviti liječenje i pratiti funkciju jetre barem svaka 2 tjedna.
&gt; 3 times ULN (Grade 2 or higher) with concurrent bilirubin &gt; 2 times ULN
&gt; 3 puta GGN (2. ili viši stupanj) uz bilirubin istodobno &gt; 2 puta iznad GGN
&gt; 3 to ≤5 x ULN
&gt; 3 do ≤ 5 x GGN
&gt; 3-10 × ULN (grade 3)
&gt; 3-10 × GGN (3. stupanj)
&gt; 30 mg/kg/day
&gt; 30 mg/kg/dan
&gt; 30 ml/min).
30 ml/min).
&gt; 30 ml/min).
&gt; 30 ml/min).
&gt; 30 to 50 mL/min
&gt; 30 i 50 ml/min
&gt; 32 weeks
&gt; 32 tjedna
&gt; 33% above pre- treatment average
&gt; 33% iznad prosjeka prije liječenja
&gt; 35 years
≥35 godina
&gt; 3X upper normal limit
&gt; trostruka gornja normalna granica
&gt; 4 units/month for an adult)
&gt; 4 jedinice/mjesec za odraslu osobu)
&gt; 4 watery stools/day or ≥2 days
&gt; 4 vodene stolice dnevno ili ≥ 2 dana
&gt; 45 minutes increase in average nighttime sleep duration
&gt; 45- minutno produljenje prosječnog trajanja noćnog sna
&gt; 45 minutes increase in average nighttime sleep duration
&gt; 45- minutno skraćenje prosječnog trajanja dnevnog sna
&gt; 480 ms in 1 patient in the pasireotide intramuscular use 40 mg group.
&gt; 480 ms u 1 bolesnika u skupini koja je primala 40 mg pasireotida intramuskularno.
&gt; 5 and ≤ 8 x ULN: Confirm levels and if confirmed stop treatment and monitor liver function at least every 2 weeks.
&gt; 5 i  8 x GGN: Potvrditi vrijednosti i ukoliko je potvrđeno, obustaviti liječenje i pratiti funkciju jetre barem svaka 2 tjedna.
&gt; 5 and  8 x ULN: Confirm levels and if confirmed stop treatment and monitor liver function at least every 2 weeks.
&gt; 5 i  8 x GGN: Potvrditi vrijednosti i ukoliko je potvrđeno, obustaviti liječenje i pratiti funkciju jetre barem svaka 2 tjedna.
&gt; 5 cm
hematom &gt; 5 cm
&gt; 5 times baseline)   * °
&gt; 5 puta početna vrijednost)   * °
&gt; 5 times ULN
&gt; 5 puta GGN
&gt; 5 to ≤10 x ULN
&gt; 5 do ≤ 10 x GGN
&gt; 5 to ≤12 years
&gt; 5 do ≤12 godina
&gt; 5 to ≤12years
&gt; 5 do ≤12 godina
&gt; 5 ULN
&gt; 5 GGN
&gt; 5% to ≤10%
&gt; 5% do ≤ 10
&gt; 5-20 × ULN* (Grade 3)
&gt; 5-20 × GGN* (3. stupanj)
&gt; 5.0 × ULN (Grade 4)
&gt; 5,0 × GGN (stupanj 4)
&gt; 5.0x ULN
5,0 x GGN
&gt; 5.5 and &lt; 6.7 mmol/l ( &gt; 100 and &lt; 120 mg/dl)
&gt; 5,5 i &lt; 6,7 mmol/l ( &gt; 100 i &lt; 120 mg/dl)
&gt; 50 to ≤60
&gt; 50 do ≤60
&gt; 50 years
≥50 godina
&gt; 50,000 copies/mL
&gt; 50 000 kopija/ml
&gt; 6 to 8 hours after first dose
&gt; 6 do 8 sati nakon prve doze
&gt; 60 to ≤70
&gt; 60 do ≤70
&gt; 60 years
&gt; 60 godina
&gt; 70 to ≤80
&gt; 70 do ≤80
&gt; 8 mg/l
&gt; 8 mg/l
&gt; 80 to ≤90
&gt; 80 do ≤90
&gt; 80 years
&gt; 80 godina
&gt; 90 to ≤100
&gt; 90 do ≤100
&gt; 99% of Xiapex-treated patients developed high titers of antibodies to both AUX-I and AUX-II.
&gt; 99% bolesnika liječenih Xiapexom razvilo je visok titar protutijela i na AUX-I i na AUX-II.
&gt; R (Resistant)
&gt; R (Rezistentni)
&gt; R (Resistant)
&gt; R (otporno)
&gt; R (Resistant)
&gt; R (rezistentna)
&gt; ULN (N=87)
&gt; GGN (N=87)
[-1.36, -0.51], p &lt; 0.0001. There was also a statistically significant improvement over placebo with the rasagiline 0.5 mg group, yet the magnitude of improvement was lower.
Također je postojalo i statistički značajno poboljšanje u razagilin 0,5 mg skupini u usporedbi s placebom, iako je razmjer poboljšanja bio manji.
[ &gt; 25 x 109/L] and/or renal impairment [CrCl &lt; 70 mL/min]) should receive prophylaxis.
[CrCl &lt; 70 ml/min]) potrebno je primijeniti profilaksu.
[CK elevation &gt; 2.5 x ULN - 5 x ULN]
[povišenje CPK &gt; 2,5 x GGN - 5 x GGN]
[CK elevation &gt; ULN - 2.5 x ULN]
[povišenje CPK &gt; GGN – 2,5 x GGN]
[CrCl] &lt; 60 ml/min or estimated glomerular filtration rate [eGFR] &lt; 60 ml/min/1.73 m2, see sections 4.3, 4.4, 4.8, 5.1 and 5.2).
[eGFR] &lt; 60 ml/min/1,73 m2, vidjeti dijelove 4.3, 4.4, 4.8, 5.1 i 5.2).
[Very common (≥ 1/10), common (≥ 1/100 to &lt; 1/10), uncommon (≥ 1/1,000 to &lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000)]
[vrlo često (≥ 1/10), često (≥ 1/100 i &lt; 1/10), manje često (≥ 1/1000 i &lt; 1/100), rijetko (≥ 1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000)]
_ _1 Diphtheria toxoid, adsorbed &gt; /= 30 IU
EU/1/00/152/021
A 1.4- to 1.7-fold increase in exposure (maximum plasma concentration and area under the plasma concentration-time curve) to selexipag and its active metabolite was observed in subjects with severe renal impairment (eGFR &lt; 30 mL/min/1.73 m2).
U ispitanika s teškim oštećenjem funkcije bubrega (eGFR &lt; 30 ml/min/1,73 m2) uočen je porast izloženosti (najveća koncentracija u plazmi i površina ispod krivulje koncentracije u vremenu) seleksipagu i njegovom aktivnom metabolitu za 1,4 do 1,7 puta.
A 10 kg change in body weight from 76 kg (median weight in the Phase 3 studies) would result in &lt; 10% change in dasabuvir exposures.
Promjena od 10 kg pri tjelesnoj težini od 76 kg (medijan težine u fazi 3 ispitivanja) rezultira u &lt; 10% promjene u izloženosti dasabuviru.
A 10 kg change in body weight from 76 kg (median weight in the Phase 3 studies) would results in &lt; 10% change in ombitasvir exposures, and no change in paritaprevir exposures.
Promjena od 10 kg pri tjelesnoj težini od 76 kg (medijan težine u ispitivanjima fazi 3) rezultira u &lt; 10% promjene u izloženosti ombitasviru te nema promjene u izloženosti paritapreviru.
A 15 minute infusion time has not been studied in cancer patients with CLCr &lt; 50 mL/min.
Nije provedeno ispitivanje 15-minutne infuzije u bolesnika oboljelih od raka s CLcr &lt; 50 ml/min.
A 4-fold increase in serum neutralising antibody against A/Indonesia/5/2005 was achieved in &gt; 90% of subjects after two doses regardless of the schedule.
Neovisno o primijenjenom režimu, nakon dvije doze u &gt; 90% ispitanika postignuto je četverostruko povećanje neutralizirajućih protutijela protiv A/Indonesia/5/2005 u serumu.
A 50% reduction in the initial and maintenance dose of Trobalt is recommended in patients with moderate or severe renal impairment (creatinine clearance &lt; 50 ml/min; see section 5.2).
U bolesnika s umjerenim ili teškim oštećenjem bubrega (klirens kreatinina &lt; 50 ml/min; vidjeti dio 5.2) preporučuje se smanjenje početne doze i doze održavanja lijeka Trobalt za 50%.
A Adverse reactions reported in ≥ 2 % of subjects treated with the combined use of saxagliptin + dapagliflozin in the pooled safety analysis, or if reported in &lt; 2 % in the pooled safety analysis, they were based on the individual mono-components data.
A Nuspojave prijavljene kod ≥ 2% ispitanika liječenih kombinacijom sakstagliptin + dapagliflozin u objedinjenoj analizi sigurnosti ili prijavljeni kod &lt; 2% bolesnika u objedinjenoj analizi sigurnosti, bazirali su se na podacima za individualne monokomponente.
a ANC &lt; 0.5 x 109/l
aABN &lt; 0,5 x 109/l
A basal antral follicle count &gt; 20.
Bazalni broj antralnih folikula &gt; 20.
A central analysis of ECG data demonstrated new QTc &gt; 500 msec in one patient (0.2%).
Središnja analiza podataka s EKG-a pokazala je novi QTc &gt; 500 msec u jednog bolesnika (0,2%).
A clinical pharmacology study of fluticasone furoate/vilanterol showed that severe renal impairment (creatinine clearance &lt; 30mL/min) did not result in significantly greater exposure to fluticasone furoate or vilanterol or more marked corticosteroid or beta2-agonist systemic effects compared with healthy subjects.
Kliničko farmakološko ispitivanje flutikazonfuroata/vilanterola pokazalo je da teško oštećenje bubrežne funkcije (klirens kreatinina &lt; 30 ml/min) nije rezultiralo značajno većom izloženošću flutikazonfuroatu ili vilanterolu niti izraženijim sistemskim učincima kortikosteroida ili beta2-agonista u odnosu na zdrave ispitanike.
A common (≥ 1/100 to &lt; 1/10) undesirable effect associated with the use of intramuscular olanzapine in clinical trials was somnolence.
Česta nuspojava (≥ 1/100 i &lt; 1/10) povezana s primjenom intramuskularnog olanzapina u kliničkim ispitivanjima bila je somnolencija.
A comparative study in 1279 subjects who received M-M-RVAXPRO or the previous formulation (manufactured with human serum albumin) of the measles, mumps, and rubella vaccine manufactured by Merck &amp; Co., Inc. demonstrated similar immunogenicity and safety between the 2 products.
Usporedno kliničko ispitivanje u koje je bilo uključeno 1279 osoba cijepljenih s M-M-RVAXPRO ili prethodnim kombiniranim (proizvedenim s humanim serumskim albuminom) cjepivom protiv morbila, parotitisa i rubele proizvođača Merck &amp; Co., Inc. pokazalo je da ta dva cjepiva imaju sličnu imunogenost i sigurnost primjene.
A complete blood count should be obtained on Day 22 (21 days after the first dose) or within 48 hours of that day, and weekly until ANC &gt; 1.5 x 109/l and platelet count &gt; 100 x 109 /l.
Kompletna krvna slika mora se napraviti 22. dana (21 dan nakon prve doze) ili unutar 48 sati od tog dana, a zatim jednom tjedno sve dok ABN ne bude &gt; 1,5 x 109/l, a broj trombocita &gt; 100 x 109/l.
A complete blood count should be obtained on Day 22 (21 days after the first dose) or within 48 hours of that day, and weekly until ANC &gt; 1.5 x 109/l and platelet count &gt; 100 x 109/l.
Kompletna krvna slika mora se napraviti 22. dana (21 dan nakon prve doze) ili unutar 48 sati od tog dana, a zatim jednom tjedno sve dok ABN ne bude &gt; 1,5 x 109/l, a broj trombocita &gt; 100 x 109/l.
A cut-off of &gt; 2% was applied
Primijenjena je granica od &gt; 2
a DAS28-defined remission (DAS28-CRP &lt; 2.6) b SDAI criterion (SDAI ≤ 3.3)
a Remisija definirana prema indeksu DAS28 (DAS28-CRP &lt; 2,6) b Prema pojednostavljenom indeksu aktivnosti bolesti (engl. simplified disease activity score, SDAI) (SDAI ≤ 3,3)
A decrease in haemoglobin levels to &lt; 10 g/dl was observed in up to 14 % of adult patients and 7 % of children and adolescents treated with ribavirin in combination with peginterferon alfa-2b or interferon alfa-2b in clinical trials.
Sniženje koncentracije hemoglobina na &lt; 10 g/dl opaženo je u najviše 14% odraslih bolesnika i 7% djece i adolescenata liječenih ribavirinom u kombinaciji s peginterferonom alfa-2b ili interferonom alfa-2b u kliničkim ispitivanjima.
A decrease in haemoglobin levels to &lt; 10 g/dL was observed in up to 14 % of adult patients and 7 % of children and adolescents treated with ribavirin in combination with peginterferon alfa-2b or interferon alfa-2b in clinical trials.
Sniženje koncentracije hemoglobina na &lt; 10 g/dl opaženo je u najviše 14% odraslih bolesnika i 7% djece i adolescenata liječenih ribavirinom u kombinaciji s peginterferonom alfa-2b ili interferonom alfa-2b u kliničkim ispitivanjima.
A decrease in haemoglobin levels to &lt; 10 g/dl was observed in up to 14% of adult patients and 7% of children and adolescents treated with ribavirin in combination with peginterferon alfa-2b or interferon alfa-2b in clinical trials.
U kliničkim ispitivanjima sniženje koncentracije hemoglobina na &lt; 10 g/dl opaženo je u najviše 14 % odraslih bolesnika i 7 % djece i adolescenata liječenih ribavirinom u kombinaciji s peginterferonom alfa•2b ili interferonom alfa-2b.
A decrease of &gt; 10% from the normal reference range at baseline for absolute neutrophil (11.2%) and red blood cell (11.1%) count, and increases &gt; 10% from the normal reference range at baseline for monocyte (16.7%) and absolute monocyte (11.2%) counts has been seen.
Uočen je pad od &gt; 10 % u odnosu na uobičajeni raspon referentnih vrijednosti kod početne vrijednosti za apsolutni broj neutrofila (11,2 %) i crvenih krvnih stanica (11,1 %) te povećanje od &gt; 10 % u odnosu na normalni raspon referentnih vrijednosti kod početne vrijednosti za broj monocita (16,7 %) i apsolutni broj monocita (11,2 %).
A dedicated study in 43 cancer patients with hepatic impairment showed no influence of mild (total bilirubin &gt; 1 to ≤1.5 x ULN or AST &gt; 1.5 x ULN) or moderate (total bilirubin &gt; 1.5 to ≤3.0 x ULN) hepatic impairment on cabazitaxel pharmacokinetics.
Posebna studija na 43 onkološka bolesnika s oštećenjem jetrene funkcije pokazala je da blago (ukupan bilirubin &gt; 1 do ≤ 1,5 x GGN ili AST &gt; 1,5 x GGN) ili umjereno (ukupan bilirubin &gt; 1,5 do ≤ 3 x GGN) oštećenje jetrene funkcije ne utječe na farmakokinetiku kabazitaksela.
A dose adjustment should be made in obese patients with BMI &gt; 30 kg/m2 (see section 4.2).
Potrebno je prilagoditi dozu kod pretilih bolesnika čija je vrijednost BMI &gt; 30 kg/m2 (vidjeti dio 4.2).
A dose escalation to a maximum of 50 mg/day may be considered in patients who tolerate a 40 mg/day starting dose (i.e. absence of diarrhoea, skin rash, stomatitis, and other adverse reactions with CTCAE Grade &gt; 1) in the first cycle of treatment (21 days for EGFR mutation positive NSCLC and 28 days for squamous NSCLC).
Povećanje doze do maksimalno 50 mg/dan može se razmotriti u bolesnika koji podnose početnu dozu od 40 mg/dan (tj. u odsustvu proljeva, osipa na koži, stomatitisa i drugih nuspojava CTCAE stupnja &gt; 1) u prvom ciklusu liječenja (21 dan za NSCLC s pozitivnom EGFR mutacijom i 28 dana za skvamozne NSCLC).
A faint/barely perceptible membrane staining is detected in &gt; 10 % of the tumour cells.
Blijeda, jedva uočljiva obojenost membrane u &gt; 10 % tumorskih stanica.
A faint/barely perceptible membrane staining is detected in &gt; 10 % of the tumour cells.
Blijeda/jedva uočljiva obojenost membrane u &gt; 10% tumorskih stanica.
A food-effect study involving administration of the film-coated tablets to healthy volunteers under fasting conditions and with a low-fat (fat content &lt; 10% of calories) or high-fat (fat content &gt; 50% of calories) meal indicated that the AUC and Cmax were slightly decreased after a low-fat meal (by 11% and 16%, respectively).
Ispitivanje učinka hrane koje je uključivalo primjenu filmom obloženih tableta u zdravih dobrovoljaca natašte te uz nemasni (sadržaj masti &lt; 10% kalorija) ili punomasni (sadržaj masti &gt; 50% kalorija) obrok ukazalo je na to da su AUC i Cmax bili blago povišeni nakon nemasnog obroka (za 11% odnosno 16%).
A greater proportion of patients treated with empagliflozin and with a baseline HbA1c ≥7.0% achieved a target HbA1c of &lt; 7% compared to placebo (Table 6).
Veći udio bolesnika liječenih empagliflozinom s početnom vrijednošću HbA1c ≥ 7,0 % postigao je ciljnu vrijednost &lt; 7 % u usporedbi s placebom (tablica 6).
A hazard ratio &lt; 1 indicates an advantage for VcR-CAP.
Omjer hazarda &lt; 1 ukazuje na prednost za VcR-CAP.
A high number of circulating lymphocytes ( &gt; 400,000/mcL) may confer increased risk.
Visok broj limfocita ( &gt; 400 000/μl) u cirkulaciji može doprinjeti povećanom riziku.
A higher incidence of sleep disorders (mainly insomnia) in patients with a baseline body weight &lt; 60 kg was observed in Study RO-2455-404-RD for patients treated with roflumilast when compared to those treated with placebo (6.0% vs 1.7%).
U ispitivanju RO-2455-404-RD zabilježena je veća incidencija poremećaja spavanja (uglavnom nesanice) u bolesnika s početnom tjelesnom težinom &lt; 60 kg koji su liječeni roflumilastom u usporedbi s onima koji su uzimali placebo (6,0% naspram 1,7%).
a Hospitalisation/emergency room treatment or treatment with oral steroids b Reduction in exacerbation rate is statistically significant (P value &lt; 0.01) for both comparisons
a Hospitalizacija/liječenje u hitnom prijemu ili liječenje oralnim steroidima b Smanjenje stope egzacerbacije statistički je značajno (P vrijednost &lt; 0,01) za obje komparativne grupe.
A hydroxyl metabolite of valsartan has been identified in plasma at low concentrations ( &lt; 10%).
Utvrđen je hidroksilni metabolit valsartana u plazmi pri niskim koncentracijama ( &lt; 10%).
A In the clinical studies, the dose of ribavirin was weight-based ( &lt; 66 kg = 800 mg/day, 66 to 80 kg = 1,000 mg/day, 81 to 105 kg = 1,200 mg/day, &gt; 105 kg = 1,400 mg/day) administered in two divided doses with food.
A U kliničkim se ispitivanjima doza ribavirina određivala prema tjelesnoj težini ( &lt; 66 kg=800 mg/dan, 66 do 80 kg=1000 mg/dan, 81 do 105 kg=1200 mg/dan, &gt; 105 kg=1400 mg/dan), a primjenjivala se podijeljena u dvije doze, zajedno s hranom.
a Intent to treat population – last observation carried forward b Adjusted mean c P &lt; 0.05 for treatment difference
a Populacija koju se namjeravalo liječiti – prijenos posljednje zabilježenih vrijednosti b Prilagođena srednja vrijednost c P &lt; 0,05 za razliku između liječenja
a Intent to treat population – last observation carried forward b Adjusted mean c P &lt; 0.05 for treatment difference
a Populacija koju se namjeravalo liječiti – prijenos posljednje zabilježenih vrijednosti b Prilagođena srednja vrijednost c P &lt; 0,05 za razliku između terapija
A key issue is to treat children aged &lt; 5 years suffering from a severe form of the disease, even though children &lt; 5 years were not included in the pivotal phase 3 study.
Ključno pitanje je liječenje djece mlađe od 5 godina koja pate od teškog oblika bolesti, iako djeca mlađa od 5 godina nisu bila uključena u ključnu studiju faze 3.
A large increase in the number of circulating lymphocytes (e.g., &gt; 400,000/mcL) has been observed in some patients.
U nekih bolesnika je uočen veliki porast broja limfocita u cirkulaciji (tj. &gt; 400 000/μl).
A large outcome study, BEAUTIFUL, was performed in 10917 patients with coronary artery disease and left ventricular dysfunction (LVEF &lt; 40%) on top of optimal background therapy with 86.9% of patients receiving beta-blockers.
Veliko ispitivanje BEAUTIFUL, provedeno je na 10 917 bolesnika s koronarnom arterijskom bolešću i disfunkcijom lijeve klijetke (LVEF &lt; 40%) koji su primali uobičajenu terapiju, i od kojih je 86,9% bolesnika primalo beta blokatore.
A large outcome study, SIGNIFY, was performed in 19102 patients with coronary artery disease and without clinical heart failure (LVEF &gt; 40%), on top of optimal background therapy.
Veliko ispitivanje ishoda, SIGNIFY, provedeno je u 19102 bolesnika s koronarnom arterijskom bolešću bez kliničkih znakova zatajenja srca (LVEF &lt; 40%) uz optimalnu osnovnu terapiju.
A limited number ( &gt; 800) of pregnant women were exposed to ritonavir during pregnancy; a very limited number ( &lt; 300) were exposed during the first trimester.
Ritonaviru je tijekom trudnoće bio izložen ograničeni broj žena ( &gt; 800), a vrlo ograničen broj bih ih je izložen ritonaviru tijekom prvog tromjesečja trudnoće ( &lt; 300).
A loading dose of 200 mg may be considered, but further dose titration ( &gt; 200 mg daily) should be performed with caution.
Može se razmotriti udarna doza od 200 mg, ali daljnju titriraciju doze ( &gt; 200 mg dnevno) treba provoditi s oprezom.
A loading dose of 200mg may be considered, but further dose titration ( &gt; 200 mg daily) should be performed with caution.
Može se razmotriti udarna doza od 200 mg, ali daljnju titraciju doze ( &gt; 200 mg dnevno) treba provoditi s oprezom.
A loading dose of 200mg may be considered, but further dose titration ( &gt; 200 mg daily) should be performed with caution.
Može se razmotriti udarna doza od 200 mg, ali daljnju titriraciju doze ( &gt; 200 mg dnevno) treba provoditi s oprezom.
A loading dose of 200mg may be considered, but further dose titration ( &gt; 200 mg daily) should be performed with caution. .
Može se razmotriti udarna doza od 200 mg, ali daljnju titriraciju doze ( &gt; 200 mg dnevno) treba provoditi s oprezom.
A major cytogenetic response is defined by &lt; 34 % Ph+ leukaemic cells in the bone marrow, whereas a minor response is  34 %, but &lt; 90 % Ph+ cells in the marrow.
Jaki citogenetski odgovor definiran je kao &lt; 34% Ph+ leukemičnih stanica u koštanoj srži, dok je slabiji odgovor definiran kao ≥ 34%, ali &lt; 90% Ph+ stanica u koštanoj srži.
A mass balance study demonstrated that &gt; 90% of the dose was excreted within 24 hours.
Ispitivanje masene bilance pokazalo je da se &gt; 90% doze izluči unutar 24 sata.
A mean decrease affecting white blood cell (WBC) count ( &lt; 15% from baseline levels, mainly neutrophil and lymphocytes decrease) was observed in placebo-controlled trials with AUBAGIO, although a greater decrease was observed in some patients.
U placebom kontroliranim ispitivanjima lijeka AUBAGIO primijećeno je smanjenje srednje vrijednosti broja leukocita ( &lt; 15% u odnosu na početne vrijednosti, uglavnom pad broja neutrofila i limfocita), a u nekih je bolesnika to smanjenje bilo još i veće.
A mean increase in total systemic exposure (AUClast) of up to 1.4 fold was seen in adult subjects with mild and moderate renal impairment (GFR ≥30mL/min/1.73m2) and up to 2.2 fold in subjects with severe renal impairment or end stage renal disease (estimated GFR &lt; 30 mL/min/1.73m2).
Srednje povećanje ukupne sistemske izloženosti (AUClast) za najviše 1,4 puta uočeno je u odraslih ispitanika s blagim i umjerenim oštećenjem funkcije bubrega (GFR ≥30 ml/min/1,73m2) te do za 2,2 puta u ispitanika s teškim oštećenjem funkcije bubrega ili sa završnim stadijem bolesti bubrega (procijenjeni GFR &lt; 30 ml/min/1,73m2).
A meta-analysis of patients with moderate to severe Alzheimer's disease (MMSE total scores &lt; 20) from the six phase III, placebo-controlled, 6-month studies (including monotherapy studies and studies with patients on a stable dose of acetylcholinesterase inhibitors) showed that there was a statistically significant effect in favour of memantine treatment for the cognitive, global, and functional domains.
Metaanaliza bolesnika s umjerenom do teškom Alzheimerovom bolešću (ukupni MMSE &lt; 20) iz šest faza III placebom kontroliranih ispitivanja u trajanju od 6 mjeseci (uključujući monoterapijska ispitivanja i ispitivanja s bolesnicima na stabilnoj dozi inhibitora acetilkolinesteraze) pokazala je da postoji statistički značajan učinak u korist liječenja memantinom u kognitivnom, globalnom i funkcionalnom području.